Overview

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Status:
Active, not recruiting

Trial end date:
2023-08-30

Target enrollment:

Participant gender:

Summary

A long term study to demonstrate the Safety and Efficacy of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab Spondyloarthritis.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Sun Pharma Global FZE
Sun Pharmaceutical Industries Limited

Treatments:

Antibodies, Monoclonal